Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of subcutaneous guselkumab in pediatric chronic plaque psoriasis
2017-003053-42Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in psoriasis (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Co-primary efficacy endpoints, Safety endpoints and 2 more. Started May 2018; status: active.
02
Drugs
guselkumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2017-003053-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003053-42.